Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck
Authors:
- 4 June 2016
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 17 (7) , 37
Abstract
The survival rate for patients with advanced stages of squamous cell carcinoma of the head and neck (SCCHN) remains poor despite multimodal treatment options. Cetuximab, an anti-EGFR inhibitor, is the only FDA-approved targeted agent for this disease. Recent findings have implicated modifications of the microenvironment and, consequently, phenotypical modifications of the cancer cell, in treatment resistance mechanisms. For many years, cancer research has focused mainly on targetable sites on or inside the cancer cell. Nowadays, in preclinical and clinical studies, a greater emphasis is being placed on drugs that target the tumor microenvironment. Potential targets relate to tumor vascularization, immunology, extracellular matrix components, or cancer-associated fibroblasts. The combination of these new agents with standard treatment options is of particular interest to overcome resistance mechanisms and/or to increase treatment efficacy. Whereas antiangiogenic agents show poor clinical activity, immunotherapy seems to be a more promising tool with an objective response rate (ORR) of 20 % in patients with recurrent and/or metastatic squamous cell carcinoma (R/M SCC). Other targets, located inside the extracellular matrix or on cancer associated fibroblasts, are under preclinical investigation. These new agents all need to be tested in clinical trials alone, or in combination with standard treatment modalities, based on preclinical data. To increase our knowledge of the complex network between the cancer cell and its environment, preclinical studies should consider co-culture models, and clinical studies should incorporate a translational research objective.Keywords
This publication has 100 references indexed in Scilit:
- Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor modelsCancer Immunology, Immunotherapy, 2013
- Discoidin domain receptor tyrosine kinases: new players in cancer progressionCancer and Metastasis Reviews, 2012
- RNAi Targeting CXCR4 Inhibits Tumor Growth Through Inducing Cell Cycle Arrest and ApoptosisMolecular Therapy, 2012
- Actomyosin-Mediated Cellular Tension Drives Increased Tissue Stiffness and β-Catenin Activation to Induce Epidermal Hyperplasia and Tumor GrowthCancer Cell, 2011
- Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinomaCancer, 2010
- Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblastsProceedings of the National Academy of Sciences, 2010
- Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent MannerCancer Cell, 2010
- CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathwayBiochemical and Biophysical Research Communications, 2007
- High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinomaJournal of Clinical Pathology, 2006
- IntegrinsCell, 2002